[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562954":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":65,"collaborators":69,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":24,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":24,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":24,"overallStatus":47,"whyStopped":24,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Thermal ablation","EXPERIMENTAL","Patients only accepted thermal ablation (microwave ablation,radiofrequency ablation)",[13],"Procedure: Thermal ablation",{"label":15,"type":10,"description":16,"interventionNames":17},"Microwave ablation plus Donafenib","Patients accepted thermal ablation (microwave ablation,radiofrequency ablation) plus Donafenib (100mg, bid)",[13,18],"Drug: Donafenib",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Thermal ablation of tumors",[15,9],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"DRUG","Donafenib","Donafenib ( 100 mg，bid)",[15],[31],{"name":32,"affiliation":33,"role":34},"Feng Duan, Professor","Chinese PLA General Hospital","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":24,"email":40},"Qunfang Zhou, MD","CONTACT","86 19868000115","zhouqun988509@163.com",{"name":32,"role":38,"phone":42,"phoneExt":24,"email":43},"86 13910984586","duanfeng@vip.sina.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Chinese PLA General hospital","RECRUITING","Beijing","None Selected","100853","China","CN",{"type":54,"coordinates":55},"Point",[56,57],116.39723,39.9075,{"lat":57,"lon":56},[60,62],{"name":61,"role":38,"phone":24,"phoneExt":24,"email":40},"Qunfang Zhou",{"name":63,"role":38,"phone":64,"phoneExt":24,"email":43},"Feng Duan","8613910984586",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Zhou Qunfang","Clinical Professor",[70],{"name":33,"class":6},"100562954","donafenib-as-adjuvant-therapy-following-ablation-for-recurrent-hcc-100562954",false,"NCT06609876","Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC","Thermal Ablation Combined With Low-dose Donafinib for Early Recurrent Hepatocellular Carcinoma: a Multicenter Prospective Study","Inclusion Criteria:\n\n1. were aged 18-75 years;\n2. had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;\n3. RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);\n4. the early RHCC (recurrent time \\\u003C1 year)\n5. patients were unwilling to undergo repeat hepatectomy or liver transplantation;\n6. had well-preserved liver function, i.e., Child-Pugh class A or B, and prolonged prothrombin time≤5 s;\n7. patients had an Eastern Cooperative Oncology Group performance status score ≤1.\n8. Ability to understand the protocol and to agree to and sign a written informed consent document.\n\nExclusion Criteria:\n\n1. were under 18 years or over 75 years of age;\n2. primary HCC;\n3. recurrent HCC beyond Milan criteria;\n4. RHCC with metastasis or macrovascular tumor thrombus","ALL","18 Years","75 Years",{"count":82,"type":83},108,"ESTIMATED","INTERVENTIONAL",[86],"NA","This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.",[89,90,27,91],"Hepatocellular Carcinoma","Microwave Ablation","Recurrent Tumor","2024-12-01",{"date":94,"type":95},"2024-12-03","ACTUAL",{"date":97,"type":95},"2024-10-01",{"date":99,"type":83},"2028-10-01",{"name":5,"class":6},1]